loading
Schlusskurs vom Vortag:
$122.85
Offen:
$122.85
24-Stunden-Volumen:
1.40M
Relative Volume:
2.21
Marktkapitalisierung:
$7.43B
Einnahmen:
$3.99B
Nettoeinkommen (Verlust:
$463.16M
KGV:
-78.32
EPS:
-1.57
Netto-Cashflow:
$1.10B
1W Leistung:
-0.06%
1M Leistung:
+3.13%
6M Leistung:
+14.54%
1J Leistung:
+2.71%
1-Tages-Spanne:
Value
$121.37
$124.39
1-Wochen-Bereich:
Value
$119.14
$126.23
52-Wochen-Spanne:
Value
$99.06
$134.17

Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile

Name
Firmenname
Jazz Pharmaceuticals Plc
Name
Telefon
353-1-634-7800
Name
Adresse
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Name
Mitarbeiter
2,800
Name
Twitter
@jazzpharma
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
JAZZ's Discussions on Twitter

Vergleichen Sie JAZZ mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
JAZZ
Jazz Pharmaceuticals Plc
122.97 7.43B 3.99B 463.16M 1.10B 7.10
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
397.27 102.31B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
701.85 77.13B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
623.82 37.30B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
245.44 31.66B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
113.08 27.11B 3.30B -501.07M 1.03B -2.1146

Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-12-12 Hochstufung Morgan Stanley Equal-Weight → Overweight
2024-06-05 Eingeleitet Goldman Buy
2024-01-03 Eingeleitet Robert W. Baird Outperform
2023-11-27 Herabstufung UBS Buy → Neutral
2023-09-29 Eingeleitet Raymond James Mkt Perform
2023-06-12 Fortgesetzt Wells Fargo Equal Weight
2022-12-09 Hochstufung Goldman Neutral → Buy
2022-06-14 Eingeleitet UBS Buy
2022-04-06 Herabstufung Goldman Buy → Neutral
2021-11-19 Fortgesetzt Goldman Buy
2021-10-07 Fortgesetzt Jefferies Buy
2021-10-05 Eingeleitet Citigroup Buy
2021-09-23 Eingeleitet Needham Buy
2021-05-19 Fortgesetzt JP Morgan Overweight
2021-04-07 Fortgesetzt RBC Capital Mkts Outperform
2021-02-05 Bestätigt H.C. Wainwright Buy
2021-02-03 Hochstufung Piper Sandler Neutral → Overweight
2021-01-29 Herabstufung Morgan Stanley Overweight → Equal-Weight
2020-12-16 Eingeleitet UBS Buy
2020-11-03 Bestätigt H.C. Wainwright Buy
2020-10-09 Bestätigt H.C. Wainwright Buy
2020-09-14 Herabstufung Goldman Neutral → Sell
2020-09-14 Fortgesetzt JP Morgan Overweight
2020-08-06 Hochstufung Morgan Stanley Equal-Weight → Overweight
2020-07-28 Hochstufung Wolfe Research Peer Perform → Outperform
2020-07-23 Hochstufung H.C. Wainwright Neutral → Buy
2020-04-06 Eingeleitet Jefferies Buy
2020-03-12 Hochstufung Bernstein Mkt Perform → Outperform
2020-01-08 Eingeleitet Goldman Neutral
2019-08-21 Herabstufung Piper Jaffray Overweight → Neutral
2019-06-11 Eingeleitet Barclays Overweight
2019-03-20 Eingeleitet SunTrust Buy
2018-12-14 Eingeleitet Wolfe Research Peer Perform
2018-11-08 Bestätigt B. Riley FBR Buy
2018-08-08 Bestätigt Stifel Buy
2018-07-11 Herabstufung Morgan Stanley Overweight → Equal-Weight
2018-03-23 Bestätigt H.C. Wainwright Neutral
2018-03-19 Hochstufung Morgan Stanley Equal-Weight → Overweight
Alle ansehen

Jazz Pharmaceuticals Plc Aktie (JAZZ) Neueste Nachrichten

pulisher
04:31 AM

Sanctuary Advisors LLC Buys 9,804 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat

04:31 AM
pulisher
Dec 18, 2024

Akari Therapeutics Names Interim CEO Patel as Permanent Chief, Adds Jazz Pharma Veteran to Board - StockTitan

Dec 18, 2024
pulisher
Dec 18, 2024

Jazz Pharmaceuticals CEO to retire by end 2025, search begins - Investing.com Australia

Dec 18, 2024
pulisher
Dec 18, 2024

Public Employees Retirement System of Ohio Makes New $2.49 Million Investment in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat

Dec 18, 2024
pulisher
Dec 17, 2024

Jazz Pharmaceuticals CEO to Present Strategic Vision at JP Morgan Healthcare Conference 2025 - StockTitan

Dec 17, 2024
pulisher
Dec 17, 2024

Big Peninsula drugmaker on the hunt for new CEO - The Business Journals

Dec 17, 2024
pulisher
Dec 17, 2024

Jazz Pharmaceuticals CEO to Retire, Succession Search Underway - Sleep Review

Dec 17, 2024
pulisher
Dec 17, 2024

Graft-Versus-Host Disease Market on Track for Major Expansion - openPR

Dec 17, 2024
pulisher
Dec 17, 2024

Jazz Pharmaceuticals Announces CEO Succession Plan - PharmiWeb.com

Dec 17, 2024
pulisher
Dec 17, 2024

Jazz Pharmaceuticals CEO to retire - MSN

Dec 17, 2024
pulisher
Dec 16, 2024

Bruce Cozadd to retire as Jazz’s CEO - BioCentury

Dec 16, 2024
pulisher
Dec 16, 2024

Bruce Cozadd to Retire as Chief Executive Officer of Jazz Pharmaceuticals plc Upon Appointment of Successor by the End of 2025 - Marketscreener.com

Dec 16, 2024
pulisher
Dec 16, 2024

Jazz Pharmaceuticals CEO to retire by end of 2025 - Investing.com South Africa

Dec 16, 2024
pulisher
Dec 16, 2024

Jazz to search for new chief as CEO plans retirement - BioPharma Dive

Dec 16, 2024
pulisher
Dec 16, 2024

Jazz Pharmaceuticals CEO to Step Down After Two Decades of Transformative Leadership - StockTitan

Dec 16, 2024
pulisher
Dec 16, 2024

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock Position Raised by Franklin Resources Inc. - MarketBeat

Dec 16, 2024
pulisher
Dec 16, 2024

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by Teachers Retirement System of The State of Kentucky - MarketBeat

Dec 16, 2024
pulisher
Dec 14, 2024

Is Now The Time To Put Jazz Pharmaceuticals (NASDAQ:JAZZ) On Your Watchlist? - Yahoo Finance

Dec 14, 2024
pulisher
Dec 13, 2024

Jazz upgraded to Overweight at Morgan Stanley after Ziihera launch - Yahoo Finance

Dec 13, 2024
pulisher
Dec 13, 2024

Morgan Stanley boosts Jazz Pharmaceuticals stock rating, sees upside with Ziihera launch - Investing.com Nigeria

Dec 13, 2024
pulisher
Dec 12, 2024

Jazz Pharmaceuticals retains stock target, Overweight rating on FDA approval By Investing.com - Investing.com Nigeria

Dec 12, 2024
pulisher
Dec 12, 2024

Morgan Stanley upgrades Jazz Pharmaceuticals shares, highlights Ziihera’s growth potential - Investing.com Nigeria

Dec 12, 2024
pulisher
Dec 12, 2024

Morgan Stanley Upgrades Jazz Pharmaceuticals (NASDAQ:JAZZ) to "Overweight" - MarketBeat

Dec 12, 2024
pulisher
Dec 12, 2024

Needham & Company LLC Reaffirms "Buy" Rating for Jazz Pharmaceuticals (NASDAQ:JAZZ) - MarketBeat

Dec 12, 2024
pulisher
Dec 12, 2024

State Street Corp Sells 71,036 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat

Dec 12, 2024
pulisher
Dec 11, 2024

Y Intercept Hong Kong Ltd Reduces Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat

Dec 11, 2024
pulisher
Dec 11, 2024

Stifel Financial Corp Has $15.83 Million Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat

Dec 11, 2024
pulisher
Dec 11, 2024

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by Jane Street Group LLC - MarketBeat

Dec 11, 2024
pulisher
Dec 10, 2024

Jazz Pharmaceuticals Showcases Evidence Reinforcing Epidiolex (CBD) Medical Benefits - Cannabis Business Times

Dec 10, 2024
pulisher
Dec 10, 2024

Two Sigma Advisers LP Purchases 84,500 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat

Dec 10, 2024
pulisher
Dec 09, 2024

CBD Drug For Tuberous Sclerosis: Caregivers Continue Epidiolex Treatment Citing Seizure Reduction And Cognitive Improvements - Benzinga

Dec 09, 2024
pulisher
Dec 09, 2024

XTX Topco Ltd Grows Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat

Dec 09, 2024
pulisher
Dec 09, 2024

Brokerages Set Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Price Target at $175.33 - MarketBeat

Dec 09, 2024
pulisher
Dec 08, 2024

BNP Paribas Financial Markets Lowers Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat

Dec 08, 2024
pulisher
Dec 07, 2024

Quantinno Capital Management LP Boosts Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat

Dec 07, 2024
pulisher
Dec 07, 2024

Celebrating International Volunteers Day: Honoring the Impa - CSRwire.com

Dec 07, 2024
pulisher
Dec 06, 2024

Jazz Pharma's Epidiolex Shows Remarkable 87% Seizure Reduction in Real-World Epilepsy Studies - StockTitan

Dec 06, 2024
pulisher
Dec 06, 2024

Jazz (JAZZ) Up 3.4% Since Last Earnings Report: Can It Continue? - Yahoo Finance

Dec 06, 2024
pulisher
Dec 06, 2024

Point72 Asset Management L.P. Acquires 86,768 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat

Dec 06, 2024
pulisher
Dec 06, 2024

Fmr LLC Reduces Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat

Dec 06, 2024
pulisher
Dec 06, 2024

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat

Dec 06, 2024
pulisher
Dec 06, 2024

Bank of Montreal Can Sells 49,214 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat

Dec 06, 2024
pulisher
Dec 05, 2024

Insider Sell: Bruce Cozadd Sells 2,000 Shares of Jazz Pharmaceuticals PLC - GuruFocus.com

Dec 05, 2024
pulisher
Dec 05, 2024

Jazz Pharma's Groundbreaking Cancer Drug Ziihera Secures NCCN Guidelines Recognition After FDA Approval - StockTitan

Dec 05, 2024
pulisher
Dec 05, 2024

Systematic Financial Management LP Purchases 29,647 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat

Dec 05, 2024
pulisher
Dec 05, 2024

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by Centiva Capital LP - MarketBeat

Dec 05, 2024
pulisher
Dec 04, 2024

Jazz Pharmaceuticals' chief accounting officer sells $6,491 in shares By Investing.com - Investing.com Nigeria

Dec 04, 2024
pulisher
Dec 04, 2024

Jazz Pharmaceuticals CEO Bruce Cozadd sells $242,340 in shares By Investing.com - Investing.com Canada

Dec 04, 2024
pulisher
Dec 04, 2024

Jazz Pharmaceuticals CEO Bruce Cozadd sells $242,340 in shares - Investing.com

Dec 04, 2024
pulisher
Dec 04, 2024

Jazz Pharmaceuticals to Showcase Breakthrough Cancer Drug Ziihera Following FDA Approval - StockTitan

Dec 04, 2024
pulisher
Dec 04, 2024

Parkman Healthcare Partners LLC Purchases New Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat

Dec 04, 2024

Finanzdaten der Jazz Pharmaceuticals Plc-Aktie (JAZZ)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Jazz Pharmaceuticals Plc-Aktie (JAZZ) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Carr Patricia
SVP, Chief Accounting Officer
Dec 02 '24
Sale
122.49
53
6,492
6,596
$17.87
price down icon 2.88%
$68.84
price up icon 2.65%
$39.39
price down icon 0.43%
$359.58
price down icon 0.16%
$176.50
price up icon 1.02%
$113.08
price up icon 1.56%
Kapitalisierung:     |  Volumen (24h):